← Leaderboards
Alberto Bosque
University Of Utah
$8,280,564
Attributed
$9,653,894
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,653,894 · 10
By mechanism
R01$3,681,952 · 2
R21$1,646,845 · 4
R61$1,393,570 · 1
R33$1,360,617 · 1
T32$908,966 · 1
R56$661,944 · 1
Top collaborators
- Rebecca Marie Lynch5 shared
- Sanjay B. Maggirwar5 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsViralIn VitroSignal TransductionClinical TrialsCell ModelReactivation From LatencyLatent InfectionViral GenesGene ExpressionMediatingCd4 Positive T LymphocytesHiv-1Genetic TranscriptionShockInfectionPathway InteractionsPharmaceutical PreparationsAgonistAntibodiesAnti-Retroviral AgentsDesignInvestigationAffect
Grant awards (31)
Ultrasensitive Env Detection Assay for Broadly Neutralizing Antibody Screening$493,865
R61 · FY2025 · AI
Training in HIV Persistence, Co-morbidities and Therapeutics$216,204
T32 · FY2025 · AI
Ultrasensitive Env Detection Assay for Broadly Neutralizing Antibody Screening$449,464
R61 · FY2024 · AI
Defining HIV Env protein expression in latently infected cells$201,875
R21 · FY2024 · AI
Training in HIV Persistence, Co-morbidities and Therapeutics$201,776
T32 · FY2024 · AI
Ultrasensitive Env Detection Assay for Broadly Neutralizing Antibody Screening$450,241
R61 · FY2023 · AI
Hormonal control of HIV latency$398,750
R01 · FY2023 · AI · contact PI
Defining HIV Env protein expression in latently infected cells$242,250
R21 · FY2023 · AI
Pathways modulating memory-like properties in NK cells and their impact on HIV control$242,250
R21 · FY2023 · AI · contact PI
Training in HIV Persistence, Co-morbidities and Therapeutics$205,359
T32 · FY2023 · AI
Hormonal control of HIV latency$398,750
R01 · FY2022 · AI · contact PI
Pathways modulating memory-like properties in NK cells and their impact on HIV control$201,875
R21 · FY2022 · AI · contact PI
Training in HIV Persistence, Co-morbidities and Therapeutics$187,021
T32 · FY2022 · AI
Hormonal control of HIV latency$398,750
R01 · FY2021 · AI · contact PI
Training in HIV Persistence, Co-morbidities and Therapeutics$98,606
T32 · FY2021 · AI
Targeting STAT SUMOylation for HIV cure strategies$661,944
R56 · FY2020 · AI · contact PI
Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents$398,750
R01 · FY2020 · AI · contact PI
Hormonal control of HIV latency$398,750
R01 · FY2020 · AI · contact PI
Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents$398,750
R01 · FY2019 · AI · contact PI
Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents$496,122
R01 · FY2018 · AI · contact PI
A family of compounds that reactivate latent HIV without T cell activation$452,022
R33 · FY2018 · AI · contact PI
A family of compounds that reactivate latent HIV without T cell activation$454,264
R33 · FY2017 · AI · contact PI
Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents$398,750
R01 · FY2017 · AI · contact PI
A family of compounds that reactivate latent HIV without T cell activation$450,738
R33 · FY2016 · AI · contact PI
Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents$320,530
R01 · FY2016 · AI · contact PI
Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents$74,050
R01 · FY2016 · AI · contact PI
A family of compounds that reactivate latent HIV without T cell activation$3,593
R33 · FY2016 · AI · contact PI
A family of compounds that reactivate latent HIV without T cell activation$149,795
R21 · FY2015 · AI · contact PI
A family of compounds that reactivate latent HIV without T cell activation$198,800
R21 · FY2014 · AI · contact PI
Reactivation of latent HIV through TLR signaling$186,250
R21 · FY2014 · AI · contact PI
Reactivation of latent HIV through TLR signaling$223,750
R21 · FY2013 · AI · contact PI